This poster is published under an
open license. Please read the
disclaimer for further details.
Keywords:
Multidisciplinary cancer care, Cancer, Comparative studies, MR-Spectroscopy, Oncology, Breast, Pathology
Authors:
S. Makkat1, A. Schiettecatte1, Y. Fierens2, K. De Pierre1, M. Carprieaux1, J. De Greve1, M. Vanhoey1, J. de Mey1; 1Brussels/BE, 2Jette/BE
DOI:
10.1594/ecr2015/C-2179
Aims and objectives
The prognosis of small breast cancers and hence the potential absolute benefit from adjuvant chemotherapy is mostly determined by the degree of aggressiveness of these cancers.
The foremost criterion to define this aggressiveness is the histological grade.
However,
a major proportion of these patients have an intermediary grade 2,
which have been clinically attributed either to a low risk or high risk groups based on the degree of cellular proliferation assessed by a genomic grading index [1].
This methodology is expensive and more difficult to implement in routine practice.
Another is the measurement of cellular proliferation with Ki67 immunohistochemistry,
but cut-offs used are variable and the method is less reproducible.
Non-invasive proton MR Spectroscopy (MRS) based choline quantification enables assessment of cellular proliferation in-vivo [2].
In this project we want to investigate the total choline estimation (tCho) with proton MR spectroscopy as an alternative,
non-invasive and less expensive method to prognostically categorize these cancers,
first by correlating the results of this method with validated methods.
The aims of our study were to check (1) whether total choline (tCho) quantified with MRS correlated with tumor grading and (2) whether in grade II tumors,
the differentiation into high and low risk groups could be made based on tCho values.